상기도 감염 치료 시장(2026-2030년)

The global upper respiratory tract infection treatment market is forecasted to grow by USD 2509.4 mn during 2025-2030, accelerating at a CAGR of 3.7% during the forecast period. The report on the global upper respiratory tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence and prevalence of upper respiratory tract infections, favorable drug pipeline is accelerating market growth, rising demand for over-the-counter drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global upper respiratory tract infection treatment market is segmented as below:

By Type

• Antibiotics
• NSAIDs and nasal decongestants
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Indication

• Common cold
• Sinusitis
• Pharyngitis
• Laryngitis

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the emergence of biologics is expediting market growth as one of the prime reasons driving the global upper respiratory tract infection treatment market growth during the next few years. Also, development of drug delivery devices to treat upper respiratory tract infections and technological advancements in treatment options will lead to sizable demand in the market.

The report on the global upper respiratory tract infection treatment market covers the following areas:

• Global upper respiratory tract infection treatment market sizing
• Global upper respiratory tract infection treatment market forecast
• Global upper respiratory tract infection treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global upper respiratory tract infection treatment market vendors that include Abbott Laboratories, AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Haleon Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services, Kenvue Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Procter and Gamble Co., Reckitt Benckiser Group Plc, Sandoz Group AG, Sanofi SA. Also, the global upper respiratory tract infection treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Upper Respiratory Tract Infection Treatment Market 2020 - 2024
  • Historic Market Size - Data Table on Global Upper Respiratory Tract Infection Treatment Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Indication segment analysis 2020 - 2024
  • Historic Market Size - Indication Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Upper Respiratory Tract Infection Treatment Market
• 6.2 Impact of Geopolitical Conflicts on Global Upper Respiratory Tract Infection Treatment Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Antibiotics - Market size and forecast 2025-2030
• 8.4 NSAIDs and nasal decongestants - Market size and forecast 2025-2030
• 8.5 Others - Market size and forecast 2025-2030
• 8.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Hospital pharmacies - Market size and forecast 2025-2030
• 9.4 Retail pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Indication

• 10.1 Market segments
• 10.2 Comparison by Indication
• 10.3 Common cold - Market size and forecast 2025-2030
• 10.4 Sinusitis - Market size and forecast 2025-2030
• 10.5 Pharyngitis - Market size and forecast 2025-2030
• 10.6 Laryngitis - Market size and forecast 2025-2030
• 10.7 Market opportunity by Indication
  • Market opportunity by Indication ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising incidence and prevalence of upper respiratory tract infections
  • Favorable drug pipeline is accelerating market growth
  • Rising demand for over-the-counter drugs
• 13.2 Market challenges
  • Side effects of NSAIDs decreasing market demand
  • Inappropriate use of antibiotics to treat upper respiratory tract infections
  • Lack of development of novel antibiotics to combat multidrug-resistant bacteria
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Emergence of biologics is expediting market growth
  • Development of drug delivery devices to treat upper respiratory tract infections
  • Technological advancements in treatment options

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.5 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.9 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.10 Haleon Plc
  • Haleon Plc - Overview
  • Haleon Plc - Business segments
  • Haleon Plc - Key offerings
  • Haleon Plc - Segment focus
  • SWOT
• 15.11 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.12 Kenvue Inc.
  • Kenvue Inc. - Overview
  • Kenvue Inc. - Business segments
  • Kenvue Inc. - Key news
  • Kenvue Inc. - Key offerings
  • Kenvue Inc. - Segment focus
  • SWOT
• 15.13 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Reckitt Benckiser Group Plc
  • Reckitt Benckiser Group Plc - Overview
  • Reckitt Benckiser Group Plc - Business segments
  • Reckitt Benckiser Group Plc - Key offerings
  • Reckitt Benckiser Group Plc - Segment focus
  • SWOT
• 15.17 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Business segments
  • Sandoz Group AG - Key news
  • Sandoz Group AG - Key offerings
  • Sandoz Group AG - Segment focus
  • SWOT
• 15.18 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations